Close Menu

SoftGenetics

The integrated products will provide a seamless workflow for interpreting next-generation sequence data from alignment through pathway analysis.

SoftGenetics said this week that its GeneMarker Human Identity software has received NDIS approval from the Federal Bureau of Investigation.

CollabRx has launched CancerRx, a new oncology application that runs on Apple's operating system. The app provides oncologists and pathologists with treatment options that are based on their patients' tumors and also offers a daily newsfeed from MedPage Today.

The National Center for Biotechnology Information has updated its Sequence Viewer tool.

Genedata has released a new version of Genedata Expressionist for Mass Spectrometry, its software for the analyzing metabolomics data.
Version 8.0 includes new workflows for integrated processing of LC- and GC-MS data.

Foundation Medicine has launched FoundationOne Heme, a next-generation sequencing-based test that looks for genomic alterations in 405 genes related to hematological cancers. The test also incorporates RNA sequencing of 265 genes to look for gene fusions.

SoftGenetics has released the latest version of its NextGene software for analyzing next-generation sequence data.

NuGen Technologies has launched its Ovation Human FFPE RNA-seq Multiplex System, which provides an end-to-end solution for strand-specific RNA-seq library prep from formalin-fixed paraffin-embedded tissue.

SoftGenetics has added a copy number variation tool to its NextGene software.

Pages

The Guardian reports that some UK physicians are calling for increased regulation of direct-to-consumer genetic tests.

US tax agency says 23andMe's genetic health test can be claimed as a medical expense for tax purposes, the Wall Street Journal reports.

Two Democratic lawmakers argue at USA Today that independent science is under attack by the Trump Administration.

In PLOS this week: networks of genes co-expressed in depression, role of minichromosome maintenance genes in lung adenocarcinoma, and more.